Abstract 7892: Multi-ancestry genome-wide association study (GWAS) of pediatric acute myeloid leukemia (AML) risk identifies four risk loci

{AML is a relatively rare pediatric hematological malignancy, but its treatment outcomes trail other acute leukemias with a 5-year survival rate at ∼70%. While genome-scale susceptibility studies of adult AML risk have been conducted, similar pediatric AML studies have not been published.1854 pediatric AML cases (diagnosis age <25y) were assembled from the Children’s Oncology Group (clinical trials AAML-03P1/0531/1031), Hospital for Sick Children (CA), International Berlin-Frankfurt-Münster Study Group (DE), and Royal Alexandra Hospital for Children (AUS). Cases were genotyped with the Illumina HumanOmni 2.5 BeadChip. Using ADMIXTURE-inferred global genetic ancestry, 1355 cases were grouped in African (AFR